Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

“In the two years we have worked together, Mike has demonstrated strong leadership during our Fit for Growth program, and he has been an important and valued counsel for me and our team,” Biogen CEO ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

The company's CEO warned on Wednesday that U.S. revenue for Leqembi, which it developed in partnership with Eisai Inc., “continues to be below the expectations of our collaboration.” ...

Dr. Williams previously served as the President of Research and Development at Sana Biotechnology and was CEO of Codiak ...

I look forward to us providing updates as this trial advances. At the same time, Biogen CEO Chris Viehbacher conceded that "we're still spending hundreds of millions of dollars every year on the ...

On the “anniversary” of Leqembi’s broader launch last fall, Biogen CEO Chris Viehbacher said the company has already learned a great deal about what it will take for Leqembi to succeed ...

Biogen has slashed jobs and pulled the plug on less promising drug candidates as part of a series of cost-saving measures, as CEO Christopher Viehbacher takes the lead to bring the cash-strapped ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Looking forward, Chris Garabedian, CEO of Xontogeny and Venture portfolio ... (see more details here) Biogen Inc.’s (NASDAQ:BIIB) approach can be traced back to the 2003 merger of Idec (the ...